Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib.

[1]  W. Tillett,et al.  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 , 2020, Annals of the Rheumatic Diseases.

[2]  Samuel J. Hinshaw,et al.  Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells , 2020, Molecular vision.

[3]  R. Cimaz,et al.  JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis , 2020, Clinical Rheumatology.

[4]  J. Silverberg,et al.  Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. , 2019, Journal of Allergy and Clinical Immunology.

[5]  D. Heijde,et al.  Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial , 2019, The Lancet.

[6]  A. Heiligenhaus,et al.  Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis , 2019, Ocular immunology and inflammation.

[7]  P. Emery,et al.  Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study , 2019, The Lancet.

[8]  T. Margolis,et al.  Tofacitinib for refractory uveitis and scleritis , 2018, American journal of ophthalmology case reports.

[9]  N. Bornfeld,et al.  Vasoproliferative tumours of the retina , 2000, The British journal of ophthalmology.

[10]  C. Lowder,et al.  Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. , 1999, Ocular immunology and inflammation.